Trxade Group (NASDAQ: MEDS) was featured in a recent
equity research report published by Dougherty & Company LLC. The report
reads, “We are initiating coverage of Trxade with a Buy rating and Price Target
of $12. MEDS’ primary offering is a web-based platform connecting large
suppliers of branded and generic drugs with retail and independent pharmacies.
The platform offers full price transparency, comparing the prices and
availability across a variety of suppliers. Its latest offering is a
direct-to-consumer application equipped with telemedicine visits which includes
home delivery of medications. MEDS nearly doubled revenue in 2019 and we model
the company increasing sales at close to a 40% clip in 2020, while profitable
for several quarters. We view the stock as a compelling, under-the-radar idea
for small-cap growth investors seeking exposure to digital health and telemedicine.
Our $12 Price Target is based on a 6x multiple on our 2021 forecast, a slightly
lower multiple than comps which we justify with a small cap discount, but
considering also MEDS’ superior growth rate.”
To request access to the full report, visit http://ibn.fm/LQ1QX
About Trxade Group, Inc.
Headquartered in Tampa, Florida, Trxade Group, Inc. (NASQAQ:
MEDS) is an integrated drug procurement, delivery and healthcare platform that
enables price transparency and increased profit margins to buyers and sellers
of pharmaceuticals, makes healthcare services affordable and accessible across
all 50 states, and steps in to meet today’s immediate demands. Founded in 2010,
Trxade Group is comprised of four synergistic operating platforms; the Trxade
B2B trading platform with 12,100 registered pharmacies, a licensed virtual
Wholesaler, affordable healthcare via its Bonum Health app or web-based
telehealth services, and same day or mail order pharmacy delivery capabilities
via its DelivMeds app featuring its extensive nationwide distribution network.
For additional information, please visit www.Trxade.com.
NOTE TO INVESTORS: The latest news and updates
relating to MEDS are available in the company’s newsroom at http://ibn.fm/MEDS
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
